Nissay Asset Management Corp Abb Vie Inc. Transaction History

Nissay Asset Management Corp

$15.5 Billion
Q3 2024

A detailed history of Nissay Asset Management Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Nissay Asset Management Corp holds 219,637 shares of ABBV stock, worth $37.4 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares

219,637

Previous 217,001 1.21%

Holding current value

$37.4 Million

Previous $37.2 Million 16.53%

% of portfolio

0.28%

Previous 0.25%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $431,882 - $525,433	2,636 Added 1.21%	219,637 $43.4 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $892,673 - $1.04 Million	5,767 Added 2.73%	217,001 $37.2 Million
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $29,247 - $33,324	183 Added 0.09%	211,234 $38.5 Million
Q4 2023 Feb 14, 2024	SELL	$137.6 - $154.97 $76,643 - $86,318	-557 Reduced 0.26%	211,051 $32.7 Million
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $271,321 - $314,094	2,031 Added 0.97%	211,608 $31.5 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $1.23 Million - $1.53 Million	-9,305 Reduced 4.25%	209,577 $28.2 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $1.09 Million - $1.26 Million	-7,571 Reduced 3.34%	218,882 $34.9 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $859,596 - $1.03 Million	-6,215 Reduced 2.67%	226,453 $36.6 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $984,698 - $1.13 Million	7,337 Added 3.26%	232,668 $31.2 Million
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $1.31 Million - $1.66 Million	9,492 Added 4.4%	225,331 $34.5 Million
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $489,381 - $607,185	3,708 Added 1.75%	215,839 $35 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $552,512 - $699,087	5,143 Added 2.48%	212,131 $28.7 Million
Q3 2021 Nov 10, 2021	BUY	$106.4 - $120.78 $1.23 Million - $1.4 Million	11,593 Added 5.93%	206,988 $22.3 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $2.76 Million - $3.07 Million	-26,188 Reduced 11.82%	195,395 $22 Million
Q1 2021 May 11, 2021	SELL	$102.3 - $112.62 $442,447 - $487,081	-4,325 Reduced 1.91%	221,583 $24 Million
Q4 2020 Feb 08, 2021	BUY	$80.49 - $108.67 $2.38 Million - $3.21 Million	29,528 Added 15.04%	225,908 $24.2 Million
Q3 2020 Oct 20, 2020	SELL	$85.91 - $100.83 $1.83 Million - $2.15 Million	-21,298 Reduced 9.78%	196,380 $17.2 Million
Q2 2020 Jul 27, 2020	BUY	$73.37 - $98.18 $3.56 Million - $4.77 Million	48,568 Added 28.72%	217,678 $21.4 Million
Q1 2020 May 05, 2020	BUY	$64.5 - $97.79 $451,048 - $683,845	6,993 Added 4.31%	169,110 $12.9 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $81,579 - $102,072	-1,131 Reduced 0.69%	162,117 $14.4 Million
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $261,933 - $314,919	4,159 Added 2.61%	163,248 $12.4 Million
Q2 2019 Aug 07, 2019	SELL	$65.7 - $83.98 $78,183 - $99,936	-1,190 Reduced 0.74%	159,089 $11.6 Million
Q1 2019 May 03, 2019	SELL	$77.14 - $90.79 $568,136 - $668,668	-7,365 Reduced 4.39%	160,279 $12.9 Million
Q4 2018 Feb 06, 2019	SELL	$77.85 - $96.01 $493,257 - $608,319	-6,336 Reduced 3.64%	167,644 $15.5 Million
Q3 2018 Oct 30, 2018	SELL	$88.91 - $98.84 $540,128 - $600,453	-6,075 Reduced 3.37%	173,980 $16.5 Million
Q2 2018 Aug 08, 2018	BUY	$89.78 - $106.23 $121,831 - $144,154	1,357 Added 0.76%	180,055 $16.7 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $1.97 Million - $2.64 Million	-21,408 Reduced 10.7%	178,698 $16.9 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $17.9 Million - $19.7 Million	200,106	200,106 $19.4 Million

Others Institutions Holding ABBV

# of Institutions

3,817

Shares Held

1.25B

Call Options Held

13M

Put Options Held

10M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $301B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.

Account

Nissay Asset Management Corp Abb Vie Inc. Transaction History